I read with great interest the article published by Abtahi et al recently.1 The authors aimed to investigate the association between concomitant use of oral glucocorticoids (GCs) and proton pump inhibitors (PPIs) and the risk of osteoporotic fractures among patients with rheumatoid arthritis.1 The study showed that concomitant current use of oral GCs and PPIs was associated with increased risk of osteoporotic fractures compared with non-use (adjusted HR: 1.60, 95% CI: 1.35 to 1.89). Both oral GC and PPI use alone were also associated with increased risk of osteoporotic fracture compared with non-use (adjusted HR: 1.23, 95% CI: 1.03 to 1.47 (oral GC use alone); adjusted HR: 1.22, 95% CI: 1.05 to 1.42 (PPI …